[go: up one dir, main page]

BR0001029A - Processo de transformação de células tumorais - Google Patents

Processo de transformação de células tumorais

Info

Publication number
BR0001029A
BR0001029A BR0001029-4A BR0001029A BR0001029A BR 0001029 A BR0001029 A BR 0001029A BR 0001029 A BR0001029 A BR 0001029A BR 0001029 A BR0001029 A BR 0001029A
Authority
BR
Brazil
Prior art keywords
transformation
tumor cells
cellulumumums
cryopreserved
seventy
Prior art date
Application number
BR0001029-4A
Other languages
English (en)
Inventor
Fernando Thome Kreutz
Original Assignee
Fk Biotecnologia Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fk Biotecnologia Ltda filed Critical Fk Biotecnologia Ltda
Priority to BR0001029-4A priority Critical patent/BR0001029A/pt
Priority to AU46263/01A priority patent/AU4626301A/en
Priority to PCT/BR2001/000045 priority patent/WO2001077301A1/en
Publication of BR0001029A publication Critical patent/BR0001029A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Agression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROCESSO DE TRANSFORMAçãO DE CELULASTUMORAIS". Onde recolhe-se tecido tumoral (01) e submete-se-oa fragmentação (02) e cujas células assim separadas sãocolocadas em meio de cultura RPMI - 1640, ou outra, adicionadode suplementos (03), constituídos de soro bovino fetal, glicose,insulina, antibióticos e outros. Após se estabelecerem em culturaserão incubadas com Interferon (04) (IFN) por setenta e duas horase após irradiadas (06) com dose letal e criopreservadas (07).
BR0001029-4A 2000-04-10 2000-04-10 Processo de transformação de células tumorais BR0001029A (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR0001029-4A BR0001029A (pt) 2000-04-10 2000-04-10 Processo de transformação de células tumorais
AU46263/01A AU4626301A (en) 2000-04-10 2001-04-09 Tumor cells transformation process
PCT/BR2001/000045 WO2001077301A1 (en) 2000-04-10 2001-04-09 Tumor cells transformation process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0001029-4A BR0001029A (pt) 2000-04-10 2000-04-10 Processo de transformação de células tumorais

Publications (1)

Publication Number Publication Date
BR0001029A true BR0001029A (pt) 2001-11-20

Family

ID=3943798

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0001029-4A BR0001029A (pt) 2000-04-10 2000-04-10 Processo de transformação de células tumorais

Country Status (3)

Country Link
AU (1) AU4626301A (pt)
BR (1) BR0001029A (pt)
WO (1) WO2001077301A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013210783B2 (en) 2012-01-20 2017-12-07 Cellvax Therapeutics Inc. Autologous cancer cell vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6427994A (en) * 1993-03-19 1994-10-11 Boehringer Ingelheim International Gmbh Process for preparing cancer vaccines
CA2176257A1 (en) * 1993-11-10 1995-05-18 George Blanck Reestablishment of ifn-.gamma. inducibility or constitutive expression of mhc class ii in tumor cells

Also Published As

Publication number Publication date
AU4626301A (en) 2001-10-23
WO2001077301A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
Cohen et al. A nerve growth-stimulating factor isolated from sarcom as 37 and 180
Gross et al. Collagenolytic activity in amphibian tissues: a tissue culture assay
TR200401091T4 (tr) Gelişim faktörleri ve L-glutamin içeren hücre kültürü besiyeri
JPH06511262A (ja) 非光合成で不稔の糸状細菌のエンベロープ又はエンベロープの或る部分を含有する医薬生成物、特に免疫調整用医薬生成物及びその製造
Goslen et al. Stimulation of skin fibroblast collagenase production by a cytokine derived from basal cell carcinomas
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
ATE252646T1 (de) Produktion von beta -glukan-mannan präparationen mittels autolyse von zellen unter bestimmten ph-, temperatur- und zeit bedingungen
EP0216742A3 (en) Growth factors
Dresden et al. The collagenolytic enzyme of the regenerating limb of the newtTriturus viridescens
Jones et al. Activated macrophages digest the extracellular matrix proteins produced by cultured cells
BR112014028551A2 (pt) meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
BR9609026A (pt) Composição processo para o tratamento do cáncer e de detecção para a produção de citicina por tumores para determinar a eficácia de um autólogo e kit diagnóstico para detecção para eficácia de compostos celulares autólogos
Drocourt et al. Structural requirements of (2′–5′) oligoadenylate for protein synthesis inhibition in human fibroblasts
CN107349220A (zh) 一种包含成纤维细胞外泌体的制剂及其用途
Renn Medical and biotechnological applications of marine macroalgal polysaccharides
BR0001029A (pt) Processo de transformação de células tumorais
JPH01501121A (ja) リンホカイン活性化キラー細胞増殖用無血清培地
KR920700290A (ko) 뉴클레오시드의 제조법
DE60035515D1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
Rikihisa et al. Taenia taeniaeformis: characterization of larval metabolic products and growth of host gastric cells in vitro
Fullmer Collagenase and periodontal diseases: a review
Unissa et al. Evaluation of in vitro anti-proliferative activity of L-arginine deiminase from novel marine bacterial isolate
Kirkpatrick et al. Influence of zinc and copper on lapine articular chondrocytes in monolayer culture: morphology, proliferation and proteoglycan synthesis
Sakuragawa et al. Effects of dimethylsulfoxide on sphingomyelinase in cultured human fibroblasts and correction of sphingomyelinase deficiency in fibroblasts from Niemann-Pick patients
Fjelde Observations on a human tumour in tissue culture

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A 3A ANUIDADE DE ACORDO COM A TABELA VIGENTE, REFERENTE A GUIA 240585385515.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO 016090002871 DE 13/05/2009 EM VIRTUDE DO DIPOSTO NO ART 219, INCISO I DA LPI.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE14/10/2008.

B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO REQUERIDA ATRAVES DA PETICAO NO 16100004609/RS DE 18.08.2010, UMA VEZ QUE NAO FICOU COMPROVADA A JUSTA CAUSA, CONFORME DEFINIDA NO ART. 221 DA LPI 9279/96 E NO ART. 2O DA RESOLUCAO 116/04. A COPIA DO PARECER PODERA SER SOLICITADA ATRAVES DO FORMULARIO 1.05. DESTA DATA CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ., 10A E 11A ANUIDADES.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2138 DE 27/12/2011.